The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for onabotulinumtoxinA in the indication of masseter muscle prominence. The acceptance moves the file into substantive review; it is not an approval.

Masseter prominence refers to visible enlargement of the masseter muscle at the angle of the jaw, often producing a wider, squarer lower face. Although neurotoxin injection in this muscle for cosmetic slimming has become a routine request in medical aesthetics, practice to date has run largely off-label in the United States. An FDA-cleared indication would formalize the procedure for US injectors and provide a regulatory anchor for the lower face.

What an FDA label changes for injectors

For clinicians performing lower-face contouring, a labeled use typically standardizes patient consent language, dose documentation and outcome tracking. Practices can also secure manufacturer training resources and align marketing claims with the approved indication—relevant territory given FTC scrutiny of aesthetic-service advertising and the growing willingness of state boards to discipline off-label promotion.

Practitioners should expect the eventual label, if approved, to specify unit dosing per side, treatment intervals and adjacent therapeutic claims. The scope of that label—strictly cosmetic, or also touching bruxism and TMJ disorders—will determine reimbursement pathways, since functional claims open the door to medical-insurance billing rather than patient cash pay.

A new frontline for the aesthetic neurotoxin market

OnabotulinumtoxinA has anchored the upper face for cosmetic use, with current approvals covering glabellar lines, lateral canthal lines and forehead lines. Masseter prominence would shift the franchise into the lower face, a region where competing neuromodulators have already marketed aggressively through continuing-education channels and peer-to-peer training.

The FDA's willingness to accept this sBLA suggests the lower-face regulatory pathway remains open. Rival manufacturers with approved aesthetic neuromodulators will weigh whether to commit similar filings or accept the off-label status quo. The first mover with a label likely captures formulary spots at large aesthetic chains and group practices.

What the FDA is actually reviewing

An sBLA submission for a new cosmetic indication typically contains phase 3 efficacy data with photographic or measurement endpoints, safety data covering duration and adverse-event rates, plus chemistry, manufacturing and controls updates if a new formulation strength is involved. Masseter claims in particular require functional data on bite force and mastication, given the muscle's role in chewing.

Standard practice sets a Prescription Drug User Fee Act (PDUFA) goal date roughly ten months from acceptance, with the date disclosed publicly in the FDA's database weeks after the acceptance letter. Acceptance itself carries no signal on the eventual outcome; it only confirms the file is complete enough to review.

What to watch next

• The PDUFA goal date disclosed after the acceptance letter.
• The indication language in any approval: cosmetic contouring only, or also functional claims around bruxism and TMJ symptoms.
• The label's specified units per side and minimum retreatment interval.
• Whether rival neuromodulator manufacturers announce parallel filings.

For non-prescription cosmetic brands and skincare formulators, masseter prominence sits inside a wider lower-face reshaping demand curve that already pulls firming actives, microcurrent devices and facial-training apps. A labeled neurotoxin option sharpens the clinical alternative against topical and device-based positioning, and dermatology practices may route jawline concerns toward injectables faster than toward adjunctive skincare.

Compliance teams at non-prescription brands should review off-label comparison claims in adjacent categories as the label emerges—claims that implicitly position a topical or device as equivalent to an injectable neurotoxin have historically triggered letters from FDA's Office of Prescription Drug Promotion. Procurement teams should expect incremental growth rather than a step-change in channel inventory, since injectables travel through physician channels rather than mass retail.